Get the Stockscreener App
2.94
7.92%
0.2157
Pre-market:
3.00
0.06
+2.04%
InspireMD Inc. stock is traded at $2.94, with a volume of 23,751.
It is up +7.92% in the last 24 hours and down -2.00% over the past month.
InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of coronary and vascular diseases. The company offers CGuard carotid embolic prevention systems for use in carotid artery applications; and MGuard prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions. It is also developing NGuard, a neurovascular flow diverter that diverts blood flow away from cerebral aneurysms in order to seal the aneurysms. InspireMD, Inc. distributes its products in Europe, Latin America, the Middle East, and Asia. The company is headquartered in Tel Aviv, Israel.
See More
Previous Close:
$2.7243
Open:
$2.82
24h Volume:
23,751
Relative Volume:
0.51
Market Cap:
$76.69M
Revenue:
$6.21M
Net Income/Loss:
$-19.92M
P/E Ratio:
-2.80
EPS:
-1.05
Net Cash Flow:
$-16.76M
1W Performance:
+10.11%
1M Performance:
-2.00%
6M Performance:
+24.58%
1Y Performance:
-5.16%
1-Day Range:
$2.80
$2.9728
1-Week Range:
$2.5001
$2.9728
52-Week Range:
$1.81
$3.42
InspireMD Inc. Stock (NSPR) Company Profile
Name
InspireMD Inc.
Sector
Industry
Phone
972 3 6917691
Address
4 Menorat Hamaor Street, Tel Aviv
Compare NSPR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NSPR
InspireMD Inc.
|
2.94 | 76.69M | 6.21M | -19.92M | -16.76M | -1.05 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
InspireMD Inc. Stock (NSPR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-07-16 | Initiated | Rodman & Renshaw | Buy |
| Mar-13-15 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-26-13 | Initiated | Oppenheimer | Outperform |
InspireMD Inc. Stock (NSPR) Latest News
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Compliance Issues And Stock Developments Hit Nasdaq Companies - Evrim Ağacı
StockNews.com Initiates Coverage on InspireMD (NYSE:NSPR) - Defense World
InspireMD : Breakthrough device in clinical trials aims to prevent strokes -January 20, 2025 at 07:59 am EST - Marketscreener.com
Here's Why We're Watching InspireMD's (NASDAQ:NSPR) Cash Burn Situation - Yahoo Finance
InspireMD (NYSE:NSPR) Coverage Initiated by Analysts at StockNews.com - MarketBeat
InspireMD (NYSE:NSPR) Now Covered by StockNews.com - Defense World
StockNews.com Begins Coverage on InspireMD (NYSE:NSPR) - Defense World
InspireMD (NYSE:NSPR) Now Covered by Analysts at StockNews.com - Defense World
InspireMD (NYSE:NSPR) Earns Sell Rating from Analysts at StockNews.com - MarketBeat
InspireMD, Inc. CFO Craig Shore to Retire, Company Initiates Search for SuccessorDecember 12, 2024 - Defense World
NSPRInspireMD, Inc. Latest Stock News & Market Updates - StockTitan
Medical device company kicks off search for next CFO - The Business Journals
InspireMD CFO Craig Shore to retire, successor search underway - Investing.com India
InspireMD CFO Retirement Amid Strategic Transition - TipRanks
InspireMD Announces Expected Retirement of its CFO Craig Shore and CFO Transition in 2025 - GlobeNewswire
InspireMD CFO to Retire After 15 Years Amid Crucial FDA Approval Timeline for Stroke Prevention Device - StockTitan
NSPR Stock May Gain as First Patient Enrolls in CGUARDIANS II Study - MSN
Lake Street Initiates Coverage of InspireMD (NSPR) with Buy Recommendation - MSN
InspireMD Announces First Patient Enrolled in CGUARDIANS II Pivotal Study - Defense World
Inspiremd Announces First Patient Enrolled in the Cguardians Ii Pivotal Study of the Cguard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures - Marketscreener.com
InspireMD Advances CGuard Prime with New Clinical Trial - TipRanks
InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR) - GlobeNewswire
InspireMD Launches Pivotal CGUARDIANS II Trial for Revolutionary Carotid Stent System - StockTitan
Head to Head Contrast: Penumbra (NYSE:PEN) vs. InspireMD (NYSE:NSPR) - Defense World
InspireMD adds medtech veteran Scott Ward to its board By Investing.com - Investing.com South Africa
InspireMD (NYSE:NSPR) Coverage Initiated at StockNews.com - Defense World
InspireMD appoints Scott R. Ward to its Board - Medical Buyer
InspireMD Appoints Scott R. Ward to Board of Directors - Defense World
InspireMD, Inc. Appoints Scott R. Ward to Its Board of Directors - Marketscreener.com
InspireMD adds medtech veteran Scott Ward to its board - Investing.com
InspireMD Strengthens Leadership with Scott R. Ward Appointment - TipRanks
InspireMD Announces Appointment of Accomplished Medical - GlobeNewswire
InspireMD Strengthens Board with Ex-Medtronic Executive Ahead of CGuard Prime FDA Decision | NSPR Stock News - StockTitan
InspireMD Third Quarter 2024 Earnings: US$0.16 loss per share (vs US$0.15 loss in 3Q 2023) - Simply Wall St
InspireMD, Inc. (NSPR) Reports Q3 Loss, Tops Revenue Estimates - MSN
InspireMD Inc (NSPR) Quarterly 10-Q Report - Quartzy
InspireMD, Inc. (NASDAQ:NSPR) Q3 2024 Earnings Call Transcript - Insider Monkey
InspireMD Inc. Faces Financial Uncertainty Amidst Ongoing Losses and Cash Flow Challenges - TipRanks
InspireMD Inc. Reports Q3 2024 Financial Results - TipRanks
InspireMD Achieves Record Q3 Revenue with CGuard Success - TipRanks
InspireMD Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
InspireMD Sets Revenue Record, Files FDA Approval for CGuard Stent Amid Wider Losses | NSPR Stock News - StockTitan
What To Expect From InspireMD Inc (NSPR) Q3 2024 Earnings - Yahoo Finance
InspireMD announces inducement grants - Medical Buyer
InspireMD Inc. Stock (NSPR) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):